ARS Pharmaceuticals Q2: Revenue Doubles, But Losses Widen and Legal Battles Mount
SPRY is trading near its 52-week low of $4.91 (8.4% above the low).
Summary
ARS Pharmaceuticals' Q2 revenue more than doubled to $33.7M, but net loss widened to $62.3M. The company disclosed new legal actions and a $12.5M license deal.
Updates
· Reuters — Management guided 2H 2026 SG&A and R&D expenses to $114-126 million and expects cash flow breakeven by end of 2027. Interim Phase 2b data for the CSU program is expected in Q1 2027.
Key Events · Earnings and Guidance · SPRY
-
Revenue Doubles, Losses Widen
Q2 2026 total revenue reached $33.7M, up 114% YoY, but net loss expanded to $62.3M from $44.9M, driven by a 43% increase in SG&A expenses.
-
Cash Position and Runway
Cash, cash equivalents, and short-term investments totaled $143.8M as of June 30, 2026, sufficient for at least 12 months per management.
-
New Legal Challenges
A securities class action was filed August 5, 2026, and a TCPA class action on July 10, 2026, adding to ongoing patent litigation with Lupin, Cipla, and Aptar.
-
New License Agreement
In July 2026, the company paid $12.5M upfront for exclusive worldwide rights to certain intellectual property, with potential future milestones and royalties.
Analysis · SPRY · Life Sciences
ARS Pharmaceuticals reported Q2 2026 revenue of $33.7 million, more than double the prior year, driven by strong neffy sales. However, the net loss widened to $62.3 million as selling and marketing expenses surged. The company faces multiple legal challenges, including a securities class action and patent litigation, while holding $143.8 million in cash and investments. The filing also reveals a new $12.5 million license agreement and an unused $200 million ATM facility.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.9% of the 1009 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SPRY was trading at $5.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $605.7M. The 52-week trading range was $4.91 to $16.65. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.